Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Human Metabolome Technologies Inc
6090Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan. Address: 246-2 Mizukami Kakuganji, Tsuruoka, Japan, 997-0052
Analytics
Zielpreis von Wall Street
–KGV
13.7369Dividendenrendite
2.37 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen 6090
Dividenden-Analyse 6090
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
1 JahrAusschüttungsquote 5-Jahres-Durchschnitt
21 %Verlauf der Dividende 6090
Bewertung der Aktie 6090
Finanzen 6090
Ergebnisse | 2019 | Dynamik |